Kosan Biosciences' Other Investors

Kosan Biosciences raised a round of funding on , .

is developing two new classes of anticancer agents: heat shock protein 90 (Hsp90) inhibitors and epothilones. Hsp90 inhibitors target multiple pathways involved in cancer cell growth and survival and …

Articles about Kosan Biosciences' Other Investors: